Literature DB >> 27064337

Cervical Anterolisthesis: A Predictor of Poor Neurological Outcomes in Cervical Spondylotic Myelopathy Patients After Cervical Laminoplasty.

Takeshi Oichi1, Yasushi Oshima, Yuki Taniguchi, Yoshitaka Matsubayashi, Hirotaka Chikuda, Katsushi Takeshita, Sakae Tanaka.   

Abstract

STUDY
DESIGN: A retrospective cohort study.
OBJECTIVE: To clarify the influence of cervical spondylolisthesis on neurological outcomes in cervical spondylotic myelopathy (CSM) patients after cervical laminoplasty. SUMMARY OF BACKGROUND DATA: Studies focusing on the surgical outcomes in CSM patients with cervical spondylolisthesis are limited.
METHODS: We retrospectively reviewed 125 CSM patients after cervical laminoplasty. Neurological outcomes were evaluated by calculating the Japanese Orthopedic Association (JOA) recovery rate at 2 years after surgery. We defined anterolisthesis as a more than 3-mm anterior vertebral displacement in a flexion radiograph and retrolisthesis as a more than 3-mm posterior vertebral displacement in an extension radiograph. We further assessed potential risk factors for poor neurological outcomes after cervical laminoplasty, including cervical alignment, degree of spinal cord compression, duration of myelopathic symptoms, diabetes mellitus, and preoperative JOA score. Multivariate logistic regression analysis was performed to investigate the risk factors for poor outcomes (JOA recovery rate <50%) after cervical laminoplasty.
RESULTS: Our study included 86 men and 39 women with mean age of 64 (range, 30-89) years. Average JOA scores were 9.9 and 13.3 points before and at 2 years after surgery, respectively. Average recovery rate was 47.2% (range, -68% to 100%), with 62 patients having poor outcomes (JOA recovery rate <50%) at 2 years after surgery. Anterolisthesis and retrolisthesis were observed in 13 and 24 patients, respectively. Multivariate logistic regression analysis revealed that the anterolisthesis was a significant risk factor for poor outcomes (JOA recovery rate <50%) after cervical laminoplasty (P = 0.01), whereas retrolisthesis did not affect the neurological outcomes (P = 0.6).
CONCLUSION: Anterolisthesis, but not retrolisthesis, is a significant risk factor for and predictor of poor neurological outcomes after cervical laminoplasty. Cervical laminoplasty should not be considered in CSM patients with anterolisthesis. LEVEL OF EVIDENCE: 2.

Entities:  

Mesh:

Year:  2016        PMID: 27064337     DOI: 10.1097/BRS.0000000000001277

Source DB:  PubMed          Journal:  Spine (Phila Pa 1976)        ISSN: 0362-2436            Impact factor:   3.468


  4 in total

1.  Laminoplasty with selective fusion at unstable segment versus laminectomy with fusion for multilevel cervical myelopathy: a case-control study.

Authors:  Lin Du; Yanzheng Gao; Changqing Zhao; Tangjun Zhou; Haijun Tian; Kai Zhang; Jie Zhao
Journal:  BMC Musculoskelet Disord       Date:  2021-05-07       Impact factor: 2.362

2.  Clinical Effects of Anterior Cervical Spondylolisthesis on Cervical Spondylotic Myelopathy After Posterior Decompression Surgery: A Retrospective Multicenter Study of 732 Cases.

Authors:  Ken Ninomiya; Junichi Yamane; Ryoma Aoyama; Satoshi Suzuki; Yuta Shiono; Yuichiro Takahashi; Nobuyuki Fujita; Eijirou Okada; Osahiko Tsuji; Mitsuru Yagi; Kota Watanabe; Takahito Iga; Masaya Nakamura; Morio Matsumoto; Ken Ishii; Narihito Nagoshi
Journal:  Global Spine J       Date:  2020-11-18

3.  Comparison of microendoscopic selective laminectomy versus conventional laminoplasty in patients with degenerative cervcical myelopathy: a minimum 2-year follow-up study.

Authors:  Yasushi Oshima; So Kato; Toru Doi; Yoshitaka Matsubayashi; Yuki Taniguchi; Sakae Tanaka
Journal:  BMC Musculoskelet Disord       Date:  2019-10-25       Impact factor: 2.362

4.  Does Spondylolisthesis Affect Severity and Outcome of Degenerative Cervical Myelopathy? A Systematic Review and Meta-analysis.

Authors:  Renato Gondar; Aria Nouri; Gianpaolo Jannelli; Karl Schaller; Enrico Tessitore
Journal:  Global Spine J       Date:  2020-10-16
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.